Official websites use .gov
Secure .gov websites use HTTPS
Some skin substitute manufacturers did not comply with new ASP reporting requirements
Some skin substitute manufacturers did not comply with new ASP reporting requirements
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Data brief (United States. Department of Health and Human Services. Office of Inspector General)
- Contributor(s):
- United States. Department of Health and Human Services. Office of Inspector General. Office of Evaluation and Inspections, issuing body.
- Publication:
- Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, March 2023
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Data Analysis
Government Regulation
Manufacturing Industry -- legislation & jurisprudence
Skin, Artificial
United States - Genre(s):
- Technical Report
- Abstract:
- Why OIG Did This Review. Ensuring the appropriate reporting of average sales prices (ASPs) is vital because the Centers for Medicare & Medicaid Services (CMS) uses them to directly calculate payments under Medicare Part B. Federal law requires manufacturers to provide CMS with the ASP for each of their Part B drugs and biologicals on a quarterly basis. Prior to 2022, ASP reporting requirements did not generally apply to manufacturers of certain Part B drugs and biologicals, including skin substitutes, although some manufacturers voluntarily reported these data. Congress addressed the reporting gap through the Consolidation Appropriations Act, 2021 (CAA), which required manufacturers of skin substitutes (and the other Part B-covered products referenced above) to begin reporting ASPs to CMS for the first quarter of 2022. What OIG Found. Despite the new legislative requirements, CMS was unable to calculate ASP-based payment amounts in the first quarter of 2023 for 30 of 68 skin substitute billing codes because their manufacturers did not report the required ASP data. According to our analysis, Part B payment amounts would be reduced substantially if ASPs were consistently reported and used, potentially leading to tens of millions of dollars in savings each quarter. However, CMS faces several unique hurdles in implementing ASP-based reimbursement for skin substitutes. For example, because skin substitutes are not actually prescription drugs, CMS cannot employ its usual methods and data sources to corroborate manufacturer-reported data on pricing and packaging. CMS is actively considering changes to the payment methodology for skin substitutes and, in January 2023, conducted a skin substitutes Town Hall to address stakeholder concerns and discuss potential payment approaches. What OIG Concludes. OIG appreciates that CMS is carefully considering its options regarding the potential impacts of different payment approaches for skin substitutes. Further, we also recognize that CMS’s current processes for collecting and validating ASP data are less effective for these products. However, every quarter in which wholesale acquisition costs/invoices are used as the payment basis for some skin substitutes potentially leads to tens of millions of dollars in higher payments for Medicare and its enrollees. Therefore, we encourage CMS to quickly address the issues identified in this report. This might include establishing interim approaches while working on a more systemic solution.
- Copyright:
- The National Library of Medicine believes this item to be in the public domain. (More information)
- Extent:
- 1 online resource (1 PDF file (10 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918715888406676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918715888406676